Reference

1. Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, Wen SW. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2014 Apr 1;175:124-8.
2. Mansoor GA, Frishman WH. Comprehensive management of hypertensive emergencies and urgencies. Heart disease (Hagerstown, Md.). 2002 Nov 1;4(6):358-71.
3. MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1983 Jul 8;3(4):193-217.
4. Abdullah A, Yusof M. Labetalol: A Brief Current Review. Pharmacophores. 2019 Nov 1;10(6):50-6.
5. Haddad B, Sibai BM. Chronic hypertension in pregnancy. Annals of medicine. 1999 Jan 1;31(4):246-52.
6. Brown CM, Garovic VD. Drug treatment of hypertension in pregnancy. Drugs. 2014 Mar;74:283-96.
7. Gallery ED. Hypertension in pregnancy: Practical management recommendations. Drugs. 1995 Apr;49:555-62.
8. Labetalol Hydrochloride Injection, USP (nih.gov)
9. Yuen PH, Taddei CR, Wyka BE, Chaudry IA. Compatibility and stability of labetalol hydrochloride in commonly used intravenous solutions. American journal of hospital pharmacy. 1983 Jun 1;40(6):1007-9.
10. Labetalol hydrochloride – drug summary. https://www.pdr.net/drug-summary/Labetalol-Hydrochloride-Injectionlabetalol-hydrochloride-1568. Accessed August 16, 2019.
11. McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. Clinical pharmacokinetics. 1984 Apr;9:157-67.
12. Carey B, Whalley ET. ??Adrenoceptor agonist activity of labetolol on the isolated uterus of the rat. British Journal of Pharmacology. 1979 Sep;67(1):13-5.
13. Riley AJ. Some further evidence for partial agonist activity of labetalol. British Journal of Clinical Pharmacology. 1980 May;9(5):517.
14. Rogers RC, Sibai BM, Whybrew WD. Labetalol pharmacokinetics in pregnancy-induced hypertension. American journal of obstetrics and gynecology. 1990 Feb 1;162(2):362-6.
15.  van de Vusse D, Mian P, Schoenmakers S, Flint RB, Visser W, Allegaert K, Versmissen J. Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. European Journal of Clinical Pharmacology. 2022 Nov;78(11):1763-76.
16.  Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. Bmj. 2014 Apr 15;348.
17. Matsuura A, Yamamoto T, Arakawa T, Suzuki Y. Oral administration of labetalol might improve not only the blood pressure but also clinical symptoms in Japanese women with gestational hypertension. Hypertension Research in Pregnancy. 2014;2(2):82-7.
18. McEvoy GK. AHFS drug information 97. American Society of Health-System Pharmacists; 1997.
19. Yasin ÖZ, KANAL Y, YAYLA Ç, editors. Güncel Kardiyak ?laçlar. Akademisyen Kitabevi; 2022 May 25.
20.  Lardoux H, Gerard J, Blazquez G, Chouty F, Flouvat B. Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. European Heart Journal. 1983 Nov 1;4(suppl_G):35-40.
21. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest. 2000 Jul 1;118(1):214-27.
22. El?Qarmalawi AM, Morsy AH, Al?Fadly A, Obeid A, Hashem M. Labetalol vs. methyldopa in the treatment of pregnancy?induced hypertension. International Journal of Gynecology & Obstetrics. 1995 May;49(2):125-30.
23. El?Qarmalawi AM, Morsy AH, Al?Fadly A, Obeid A, Hashem M. Labetalol vs. methyldopa in the treatment of pregnancy?induced hypertension. International Journal of Gynecology & Obstetrics. 1995 May;49(2):125-30.
24. Jackson SH, Beevers DG. Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma. British journal of clinical pharmacology. 1983 May;15(5):553-6.
25. Frishman WH, Michelson EL, Johnson BF, Poland MP. Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension. The American journal of medicine. 1983 Oct 17;75(4):54-67.
26. Korzets A, Danby P, Edmunds ME, Feehally J, Walls J. Acute renal failure associated with a labetalol overdose. Postgraduate medical journal. 1990 Jan;66(771):66-7.
27.  Labetalol hydrochloride (Trandate®). http://www.pharmaline.co.il/images/newsletterregistration/perrigo/2012/18062012/trandatetabdr.pdf. Accessed August 26, 2019
28. Bennett M. Do not forget about HELLP!. Case Reports. 2011 Oct 28;2011:bcr0820114693.
29. Clark JA, Zimmerman HJ, Tanner LA. Labetalol hepatotoxicity. Annals of internal medicine. 1990 Aug 1;113(3):210-3.
30. Magee LA, Abalos E, von Dadelszen P, Sibai B, Easterling T, Walkinshaw S, CHIPS Study Group. How to manage hypertension in pregnancy effectively. British journal of clinical pharmacology. 2011 Sep;72(3):394-401.
31. Trandate (labetalol) dosing, indications, interactions, adverse effects, and more (medscape.com)
32. Molvi SN, Mir S, Rana VS, Jabeen F, Malik AR. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Archives of gynecology and obstetrics. 2012 Jun;285:1553-62.